BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose® Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) Milan, December 15th, 2025 (GlobeNewswire) – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of solid tumours, is proud to announce that the…
Milan, December 1st, 2025 (GlobeNewsire) BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining approval from the Italian Ministry of Health to conduct clinical study in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of…
Milan, November 12, 2025 (GlobeNewsire) – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of solid tumours, announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has approved the Clinical Trial Application for YntraDose™ in unresectable Locally…
Milan, September 22, 2025 (GlobeNewsire) – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose®, announced today the succession of its Chief Executive Officer (“CEO”), Dr. Colin Story, to Mr. Alexis Peyroles, who was appointed as CEO.…
Milan, May 27th 2025 – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose®, announced today that an abstract was published by the American Society of Clinical Oncology (ASCO) entitled: “Preclinical study of safety and efficacy in vivo of…
Milan, February 20th 2025 – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose®, announced today that it has entered into an agreement for the exclusive global supply of BioGlue® for use in YntraDose. Artivion, Inc. (“Artivion”) manufactures, markets,…
Milan, December 16th 2024 - BetaGlue® Therapeutics S.p.A. (“BetaGlue”) an Italian clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose®, announced today that the ENEA-Tech and Biomedical Foundation (“ENEA-Tech”) has invested €6m bringing the total raised in the current funding round to €24m. This…
Milan, June 6, 2024 – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage radiotherapy company developing novel products for the personalised treatment of solid tumour cancers today announces the closing of an €8m equity financing round. The round included both existing and new investors and was led by Neva SGR S.p.A., the venture capital arm…
Milan, May 15, 2024 – BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage company developing novel radiotherapy products for the personalised treatment of solid tumour cancers today announces the appointment of Mike Cogswell as Chairman of the board and the appointment of Mike Maszy as Non-Executive Director. Mike Cogswell brings over 34 years of proven…
Milan, April 30, 2024 – BetaGlue Technologies S.p.A. (“BetaGlue” or the “Company”) a clinical-stage company developing novel radiotherapy products for the personalised treatment of solid tumour cancers today announces the name change to BetaGlue Therapeutics, the new trading name of the Company, and also a new brand identity. Alongside this, the Company also announces Yntradose®,…
